Headlines about Histogenics Corporation (NASDAQ:HSGX) have trended somewhat positive recently, according to Alpha One Sentiment Analysis. The research firm, a service of Accern, identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Alpha One ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Histogenics Corporation earned a media sentiment score of 0.10 on Alpha One’s scale. Alpha One also assigned headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the next several days.

Insider Buying and Selling by Quarter for Histogenics Corporation (NASDAQ:HSGX)

HSGX has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Histogenics Corporation from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Tuesday, May 16th. HC Wainwright set a $4.00 price objective on shares of Histogenics Corporation and gave the stock a “buy” rating in a report on Monday, March 20th. Finally, Canaccord Genuity restated a “buy” rating on shares of Histogenics Corporation in a report on Thursday, May 11th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $5.10.

Histogenics Corporation (NASDAQ HSGX) opened at 1.60 on Monday. Histogenics Corporation has a 12-month low of $1.45 and a 12-month high of $4.47. The stock’s 50 day moving average is $1.68 and its 200 day moving average is $1.71. The company’s market cap is $35.47 million.

Histogenics Corporation (NASDAQ:HSGX) last released its earnings results on Thursday, May 11th. The biotechnology company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.07. During the same quarter in the prior year, the business posted ($0.60) EPS. On average, equities analysts forecast that Histogenics Corporation will post ($1.33) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/06/19/histogenics-corp-hsgx-earning-somewhat-positive-news-coverage-report-shows-updated-updated.html.

About Histogenics Corporation

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Receive News & Stock Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related stocks with our FREE daily email newsletter.